Ihrler Stephan, Stiefel David, Jurmeister Philipp, Sandison Ann, Chaston Nicola, Laco Jan, Zidar Nina, Brcic Luka, Stoehr Robert, Agaimy Abbas
DERMPATH Muenchen, Munich, Germany.
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany.
Histopathology. 2023 Mar;82(4):576-586. doi: 10.1111/his.14840. Epub 2022 Dec 7.
The formal pathogenesis of salivary carcinosarcoma (SCS) remained unclear, both with respect to the hypothetical development from either preexisting pleomorphic adenoma (PA) or de novo and the clonal relationship between highly heterogeneous carcinomatous and sarcomatous components.
We performed clinicopathological and molecular (targeted RNA sequencing) analyses on a large series of 16 cases and combined this with a comprehensive literature search (111 cases). Extensive sampling (average 11.6 blocks), combined with immunohistochemistry and molecular studies (PA-specific translocations including PLAG1 or HMGA2 proven in 6/16 cases), enabled the morphogenetic identification of PA in 15/16 cases (93.8%), by far surpassing a reported rate of 49.6%. Furthermore, we demonstrated a multistep (intraductal/intracapsular/extracapsular) adenoma-carcinoma-sarcoma-progression, based on two alternative histogenetic pathways (intraductal, 56.3%, versus myoepithelial pathway, 37.5%). Thereby, early intracapsular stages are identical to conventional carcinoma ex PA, while later extracapsular stages are dominated by secondary, frequently heterologous sarcomatous transformation with often large tumour size (>60 mm).
Our findings strongly indicate that SCS (almost) always develops from PA, with a complex multistep adenoma-carcinoma-sarcoma-sequence, based on two alternative histogenetic pathways. The findings from this novel approach strongly suggest that SCS pathogenetically is a rare (3-6%), unique, and aggressive variant of carcinoma ex PA with secondary sarcomatous overgrowth. In analogy to changes of terminology in other organs, the term "sarcomatoid carcinoma ex PA with/without heterologous elements" might be more appropriate.
唾液腺癌肉瘤(SCS)的正式发病机制仍不清楚,无论是关于其假设的起源于先前存在的多形性腺瘤(PA)还是新发,以及高度异质性的癌性和肉瘤性成分之间的克隆关系。
我们对16例大量病例进行了临床病理和分子(靶向RNA测序)分析,并将其与全面的文献检索(111例)相结合。广泛取材(平均11.6块),结合免疫组织化学和分子研究(16例中有6例证实存在PA特异性易位,包括PLAG1或HMGA2),使得在16例中有15例(93.8%)能够通过形态发生学鉴定出PA,远远超过报道的49.6%的发生率。此外,我们基于两种替代的组织发生途径(导管内途径,56.3%;肌上皮途径,37.5%)证明了多步骤(导管内/囊内/囊外)腺瘤-癌-肉瘤进展。因此,早期囊内阶段与传统的PA恶变癌相同,而后期囊外阶段则以继发性、通常为异源性的肉瘤样转化为主,肿瘤通常较大(>60mm)。
我们的研究结果强烈表明,SCS(几乎)总是起源于PA,具有基于两种替代组织发生途径的复杂多步骤腺瘤-癌-肉瘤序列。这种新方法的研究结果强烈提示,SCS在发病机制上是一种罕见的(3%-6%)、独特且侵袭性的PA恶变癌变体,伴有继发性肉瘤样过度生长。类似于其他器官术语的变化,“伴有/不伴有异源性成分的PA恶变肉瘤样癌”这一术语可能更合适。